Good morning, ladies and gentlemen, and welcome to Impel NeuroPharma's third quarter 2021 earnings and corporate update conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions on how to participate will be given at that time. If anyone requires operator assistance during today's call, please press star then zero on your telephone. As a reminder, today's conference call is being recorded. Now, I would like to turn the conference over to Impel's Chief Financial Officer, John Leaman. Thank you, Gail, and good morning, everyone. We are delighted that you could join us today for Impel NeuroPharma's quarterly earnings conference call, during which we will review our third quarter 2021 financial results, as well as provide a general corporate update. Joining me from Impel this morning is Adrian Adams, Impel's Chairman of the Board and Chief Executive Officer, and Len Paolillo, our Chief Commercial Officer. Before we begin, I'd like to remind everyone that we have a slide presentation to accompany our conference call this morning, which can be viewed at our website at www.impelnp.com. If you are listening to this call on your telephone, you may access a synchronized slide deck on our website by choosing the link on the webcast page that says, "Click here to listen." Please go to slide two. I would also like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. With that, I will turn the call over to Adrian Adams. Adrian? Thank you, John, and good morning, everyone, and thank you for joining us. I'm both grateful and indeed excited to update you on the progress we have made since our quarter two earnings call. As I am pleased to say, we have achieved a number of significant milestones over the past few months. On this next slide number three, you will find the agenda for this morning's call. The focus of today's call is to review the launch progress of Trudhesa, including the early launch performance indicators within the large, rapidly growing, and dynamic acute migraine market. Given that this is only our second quarterly earnings teleconference, I will start off by providing a brief reminder of the investment opportunities with Impel before covering the results of our commercial launch efforts with Trudhesa. I will then turn the call over to John to review our third quarter financial results in detail. I will then close by briefly touching on the clinical development status of INP105 and summarizing our year-to-date progress against the corporate goals we set at the beginning of this year before opening the call up for your value questions. Turning now to our next slide number four. For those on the line who may be new to Impel, on this slide, I would like to take a moment to highlight a few of the key value drivers that we believe position the company for growth and success in the short, medium, and long term. First, the recent FDA approval of our first product, Trudhesa, for the acute treatment of migraine headaches, with or without aura in adults, has opened up a large and growing market opportunity for Impel with significant revenue potential. The commercial launch of Trudhesa in early October is focused around a highly targeted go-to-market strategy involving a 60-person sales force targeting 8,000 high-prescribing physicians with a heavy emphasis on neurologists. The clinical development program for our new relief product candidate, INP105, which is being evaluated for the acute treatment of agitation and aggression in autism, is also progressing. In fact, our phase II-A proof-of-concept trial, known as the CALM 201 Study, is planned to be initiated in the late quarter four 2021 timeframe. Finally, we believe that Impel NeuroPharma's proprietary POD technology and its unique approach to targeting the upper nasal space has the potential to truly transform clinical outcomes, not only for patients in the CNS area, but also in many other disease areas, given its ability to deliver rapid and consistent relief of symptoms with injection-like efficacy, but doing this in a non-invasive, convenient way. Please now refer to our next slide number five, where we'll turn to the details of our targeted commercial launch activities and strategy with Trudhesa. The commercial launch of Trudhesa is indeed off to a fast start as we continue to execute well against our key commercial priorities. The third quarter was a busy one as we hired, trained, and deployed our 60 neurologist sales specialists. The team is motivated by a mission to help patients still searching for predictable and consistent efficacy despite the many new options. We have also put in place a performance-aligned incentive scheme to reward them for strong sales achievement. Complementing our sales efforts, we have trained 75 key opinion leader speakers to deliver peer-to-peer education events covering the Trudhesa clinical data as well as its place in therapy. Additionally, our targeted digital direct-to-consumer activity has started and will increase its volume throughout quarter four and well into 2022. We are also pleased with our market access progress. Indeed, payer discussions are progressing according to plan, and the performance of our Trudhesa direct pharmacy partnership and bridge program is above expectations. Importantly, with low abandonment rates, which in turn signals high patient satisfaction. You'll see on our next slide, slide number six, that we have begun executing a very targeted approach in entering this large and competitive acute migraine market. I would like to remind you that at the end of 2020, there were 27 million prescriptions written in this market, an impressive growth of 15% year-over-year. This growth is being driven by the non-triptan segments of the market and in large part by the neurologist community. Our commercial strategy is focused on a concentrated prescriber base, which allows for coverage of 35% of the market. The 8,000 physicians we are targeting are comprised of around 5,500 neurologists and 2,500 high-prescribing primary care physicians. Importantly, these target physicians prescribe 60% of acute branded prescriptions and 65% of all DAT prescriptions. To provide an early perspective of how this smart, targeted approach to commercialization is leading to prescription productivity, I would like to turn to our next slide, slide number seven. Symphony Health data, as shown here, provides a view of our first four weeks of launch. This shows strong week-over-week growth in both prescriptions and indeed prescribers. Our own internal pharmacy data shows approximately 250 prescribers as of October 31st, giving an average of 2.5 Trudhesa prescriptions per prescriber. Not surprisingly, and indeed pleasingly, 83% of our prescribers are targets of our sales efforts. With around 660 prescriptions in just the first four weeks of launch, Trudhesa has clearly gained the attention of physicians, and the Trudhesa direct pharmacy partnership has provided a streamlined experience to patients. On this next slide, slide number eight, we are pleased with the growth in prescriptions in both our target prescribers and by how these prescribers are writing. Our launch efforts have a two-pronged progress. The first is on generating immediate uptake in prescribing, and the second is on creating depth and breadth of current prescribers. Our progress in both areas is highly encouraging. While we expected to have a high number of prescribers to be within our super targets and targets, we are pleased to see early prescribing trends among those who are non-targets. It is also encouraging to see we have a subset of prescribers that have already written more than six or even 11+ prescriptions. As you can see on this slide, it shows our efforts of making physicians aware of Trudhesa is paying off. On our next slide, slide number nine, it is clear that prescription share within our super targets provides quantitative signals that Trudhesa will hold a significant place in physicians' treatment. We are using Symphony Health new to brand data here due to the early stage of our launch where refills are minimal, but we also believe it is a leading indicator for future growth. The final week in October shows that Trudhesa is already capturing 2.4% of the new to brand market after only four weeks on market. This is very encouraging. Our super targets prescribe around about 60,000 branded acute prescriptions for new patients per quarter. This is 34% of the total acute branded new patient start market and represents the foundation for Trudhesa prescription growth in the future. I'd now like to turn to slide number 10. On this slide, we are illustrating the utilization of Trudhesa among our early prescribers. It is exciting to see that around 14% of the new patient starts are already going to Trudhesa. As this is only our first month of launch, this already shows competitive success and compares favorably to Nurtec and UBRELVY new patient shares. This illustrates not only the remaining need for efficacy in the acute treatment landscape, but the view that DHE, and more specifically Trudhesa, can fill that search for efficacy. This very much speaks to the evolving potential for Trudhesa in this large market, and importantly, in the post triptan failure market. We are very encouraged by the early receptivity Trudhesa has received among prescribers to date, and these early metrics give us confidence about the brand's short, medium, and long-term potential. Turning now to our next slide, slide number 11, I would like to summarize the early performance trends and quarter four expectations with Trudhesa. As we have reviewed, although early in the launch, the first month of launch has exceeded our expectations. We are pleased that the core tactics associated with our fundamental targeted launch are playing out as anticipated. Sales force execution has been both productive and successful, as manifest in terms of strong weekly prescription trends and growth, in terms of both the number and depth of prescribing with neurologists in particular. We anticipate, based on this strong start, that we will finish the year with around 750 unique prescribers and a prescription base of between 3,000-4,000 prescriptions. In addition, based on the status of contract discussions with key managed care, we expect to exit this year with around 40% of coverage of commercial lives. This performance base with Trudhesa will put us in a strong position for 2022 and a year which will, at a minimum, be in line with analyst expectations. With that, I will now turn the call over to John to review our financial results for the third quarter. Thank you, Adrian. On our next slide, slide number 12, you will see our financial results for the third quarter of 2021. The net product revenue for the third quarter 2021 was $0.1 million. Initial shipments of Trudhesa to specialty pharmacies began in September of 2021, ahead of our October commercial launch. Research and development expenses for the third quarter of 2021 were $5.9 million for third quarter 2021, compared to $6.1 million for the same period in 2020. The decrease was primarily due to the decrease in Trudhesa clinical expenses as the phase III study was closed. Selling, general and administrative expenses for the third quarter of 2021 were $16.3 million, which compares with $2.9 million for the third quarter of 2020. The increase in SG&A was primarily due to the ramp up in spending to support the commercial and marketing preparation for the Trudhesa launch. For the third quarter of 2021, Impel reported a net loss of $25 million or $1.24 / common share, compared to a net loss of $9.2 million or $15.56 / common share for the same period in 2020. Please now let's refer to the next slide, slide number 13. As of September 30th, 2021, the company had cash and cash equivalents of $111.3 million. In July, the company completed a $50 million debt financing, $30 million funded during the third quarter of 2021, and repaid the Avenue term loan of $10.9 million, including prepayment fee. Further, we have $20 million available to be used at the company's discretion upon meeting certain revenue milestones. In September, the company completed a follow-on public offering, resulting in net proceeds of $48.3 million. We believe we have sufficient financial resources given the debt and net equity financing to fund the operations into 2023. With that, I would like to turn the call back over to Adrian to make some closing remarks. Adrian? Thank you, John. Before closing, I did want to make a few remarks on the development status with INP105. I would like to turn your attention to this slide number 14. First, I would like to underscore the broad clinical possibilities that we see with our POD technology platform. We are clearly pleased with the recent approval of Trudhesa and pursuant to this, we believe that the POD technology has the potential to deliver numerous additional therapeutics, of which the next in line for Impel is indeed INP105. To remind everyone, INP105 is comprised of a powder formulation of olanzapine, which is the most used treatment for acute agitation and aggression, but its use is currently limited to intramuscular injection. We believe that INP105 has the potential to significantly reduce emergency room visits for patients with autism spectrum disorder. We have uncovered this as being a major unmet need as there are at least 220,000 emergency room visits a year, a large majority of which relate to patients that cannot be controlled in the home setting. Therefore, there is a significant market opportunity to bring a more humane approach to de-escalating agitation and aggression episodes in the autism patient population. The phase I study results of INP105 in healthy adults shown on this slide were published in The Journal of Clinical Psychiatry last year. The findings demonstrated that INP105 reached peak plasma levels approximately twice as fast as intramuscular olanzapine, currently marketed as Zyprexa, and ten times faster than orally disintegrating tablets. An ideal desired medication for acute agitation and aggression in autism is easy to administer, provides rapid tranquilization without excessive sedation, has a swift onset of action with sufficient duration to prevent untimely recurrence, and has low risk for adverse events and drug interactions. This is the goal with INP105. We are delighted to confirm that we're on schedule to re-initiate a phase II proof-of-concept study towards the end of the fourth quarter. Turning now to our final slide, slide number 15. This continues to be an exciting and transformative time for Impel, given the excellent progress we have made this year, not only achieving but exceeding the objectives and milestones we articulated at the beginning of 2021. These milestones, as you can see, include the completion of the initial public offering and successful following offerings, as well as the FDA approval and commercial launch of our first product, Trudhesa, transitioning Impel into a commercial company. We are looking forward to initiating the phase II proof-of-concept study with INP105 in the fourth quarter and to completing what has been a transformational year for Impel. With that, I'd now like to open the call up for your valued questions. Operator, can you please give the instructions? Your first question comes from the line of Ken Cacciatore from Cowen. Your line is open. Hey, team. I have a few. Congratulations on all the initial progress. I just want to start with managed care, and you talked about having 40% covered lives as we exit, which is fantastic. Wanted to drill down a little bit to talk about the net pricing that you're hoping for, how those initial discussions are going. We see Nurtec and UBRELVY settling in around $500 net to the company. Just wondering if you could give a little bit of commentary around how those discussions are progressing and how we should think about when we get to normalization, what that might look like. Really intrigued and appreciate the commentary around the view into 2022. There is a large range from just a few analysts that are following you. I think consensus shakes out in that range around $50 million. Wondering if you could just speak to it with a little bit more specificity. That was question number two, and I have a couple of follow-ups, but I'll stop there and let you answer those. Thanks. Yeah, thank you very much, Ken. I think I'll ask Len to comment in a moment. You're right. I think as you may recall, I think during the kind of May, June, and July timeframe, we invested in market access strategy professionals. That was with a view to having clinical data exchange with those groups for the very aim of making sure that we could actually transition into the launch into the fourth quarter with a strong building growth of commercial lives coverage. In essence, by the middle of next year, we anticipate 70%-75% of commercial lives being covered. Clearly, I think we've been making some very good progress. On the specifics of how those discussions are going, particularly as it relates to the actual contracts, I'm going to ask Len to comment on that. Len? Sure. Thanks, Adrian, and thanks, Ken. They're progressing exactly as we thought they would. I think one of the great things is where the company sees Trudhesa positioned, which is firmly, you know, after triptans, and you think about where the plans want to put into utilization management, we see good alignment there, right? It's that big hurdle is kind of something that we get through pretty well with the plans when they look at the clinical data for Trudhesa. At this point, it's as you expect, we're in the final stages of discussions on contracts with the large PBMs and then pulling that through to the local plan. At this stage, the conversations have gone very well. They understand the clinical data, thanks to our medical affairs and market access colleagues doing the work ahead of launch. We're in contract review with a number of the major PBMs right now. To your second question, John, maybe you can just broadly comment on our aspirations for next year. We are very pleased with the progress to date. Clearly, I think, we believe at a minimum, we're gonna be in line with the analyst expectations. John, maybe you can comment? Yeah, Ken, thanks for the comment. I think to your question, you know, as Adrian mentioned, I think we're very pleased with how the launch has gone. I think the script that he mentioned toward, you know, doing it for 2021 will lead us to hit those expectations that we're hoping to hit in 2022. When we look at the analyst expectations for 2022, you know that there's sort of a broad range, right? Yourself, Guggenheim, and Wedbush. I think as we think about, you know, what the range looks like for net revenue as we go into that year, we will be within, you know, the range of that. I think you're on the low end, and there's a couple who are on the high end. I think we think about it, you know, targeting. I think, you know, how you've laid out 2022 and 2023 is, you know, in line with, you know, what we're hoping to do in the coming year. Okay, that's helpful. Maybe just a couple other further questions. On spending, just wondering as we go into 2022 and we're looking into Q4, should we think of a slight step up into Q4? Or is Q3 a good run rate as we kind of look forward into 2022? A broader question, understanding that you'd certainly want to secure managed care before you get a little bit more aggressive on promotion. Wondering if DTC is in the future at any point later next year. Obviously, that's great to activate patients. It certainly can also help with your effort to activate clinicians. Just wondering, any thoughts, and I'll leave it there. Thanks so much, and congratulations again on the progress. Thank you, Ken. I'll ask John in a moment to comment on the aspects of spend. To your second point, I think you're quite right. I think clearly we've seen the power in the marketplace on direct-to-consumer advertising, et cetera. We are delighted that that's been driving a tremendous amount of growth within the migraine market. I think as you also know, I think we've always stressed, I think, a very financially disciplined and importantly targeted approach to our commercialization. So as we progress into 2022, we'll increase our activity in relation to kind of digital work and direct-to-consumer broad kind of digital advertising. We... You know, based on performance, we anticipate that 2022 is going to be a strong year based on that performance. There are two things that obviously we're gonna be keeping a very close eye on. One is indeed, you know, whether or not there is an opportunity to broaden the awareness and consequent generation of prescriptions with the broader utility of direct to consumer vehicles. As we've articulated before, we are planning to invest into the opportunity and with a view to doubling the size of our sales force as we move into 2023. All of this clearly is gonna be dictated by what we anticipate as being a strong first half of next year. Financial discipline, very targeted, looking in particular to build a very strong base of utility and endorsement by neurologists and then broaden that out and earning the right and the ability to be able to do more extensive promotion and direct consumer activity. John, maybe you can comment on the spend levels? Ken, I think to your question, I think the third quarter is probably a pretty good caveat as we move forward into the fourth quarter and then into 2022. I think obviously we were ramping up for basically, you know, the sales force and to get ready to go out and launch Trudhesa. I think it's a very good sort of, you know, that number is a very good one carrying forward into the next couple of quarters. Great. Thanks again. Thank you, Ken. Your next question comes from the line of Eddie Hickman from Guggenheim Securities. Your line is open. Hi, good morning, guys. Thanks for taking my question, and congrats on the launch so far. Couple from me. When you're showing here that in the, you know, sort of current four weeks for Trudhesa, you're getting almost 14% of the new-to-brand starts. Given your sort of guidance for 2022 within the analyst range and 3,000-4,000 scripts, like, what percentage sort of target does that indicate within sort of that new-to-brand starts within the competitors? Then sort of what are you looking for in 2022 that would sort of make you decide whether and when to ramp up your sales force and sort of what how much would that cost and when? Thanks. Yeah. Again, I'll ask Len to comment. We're pleased that obviously you noted that data and clearly while it's relatively early days and looking at the kind of share evolution, this is among obviously Trudhesa prescribers. We're very, you know, as you well know, I think, we've had quite a number of discussions over the course of time as to where we saw Trudhesa fitting in the physicians' armamentarium. We always said that Trudhesa should be placed post triptan failure and competing directly with UBRELVY and Nurtec. Clearly this early data gives us kind of optimism and indeed excitement around the kind of shares we're already generating. Now, clearly, over the course of the next number of months, we're gonna kind of see a lot of different dynamics going on, but this is very encouraging data so far. Len, do you wanna add to that? Yeah. I think the question around the long-term share, you know, what we're talking about here is a new-to-brand share among people that have prescribed Trudhesa already. When you look within our super targets, which are the top 2,000 of our targets, I think what we see through Q4 is achieving about a 3.5% share of that branded acute new-to-brand market, and that sets us up to that foundation in 2022. To touch on the second part of your question, which was, you know, what are some of the things that we look at to expand the size of the sales force? Well, you know, it's twofold. Obviously, you wanna see in market prescription progression, which we believe we will see, but also net price. We wanna make sure that our payer contracts are pulled through so that as we expand our sales force and begin to generate more volume with that expansion, that that's profitable volume. Getting a little bit deeper, you wanna look at your just in market sales force activity metrics. As we see that we have the opportunity to go lower down in the deciles, that's when we would add additional sales force to tighten up the size of some of the territories so that we can increase some frequency. Really it comes down to that prescription evolution and then the securing of our net price. To add, I think, you know, I would just add as well that I'll just remind you of one of the slides we showed, a number of months ago, in fact, indeed on our first earnings call, I think. That demonstrated that if you actually looked at prescriptions that have been written for Nurtec and UBRELVY since launch, around about 75%-80% of prescriptions have come from around about 5,000-5,500 physicians with a strong focus on neurologists. I only emphasize that because, you know, this data shows that that targeted strategy that we've got in place is working in practice. We are focusing on those physicians that are well aware of and supportive of DAT and see the right place in physicians' armamentarium. Clearly, I think I've always mentioned that the first and second quarter of next year are very important from a trajectory point of view. We are very pleased with where we are, and I'm looking forward to having that decision to make in relation to gradually investing into this opportunity and growing the size of the sales force. Decisions on that will be dictated by what we anticipate as being strong growth with the Trudhesa as we move through next year. Great. Then just really quickly on the 105 program, can you just talk just broadly if there are any sort of additional risks with using sort of a powder formulation within the POD technology versus a liquid formulation and sort of how we should think about those PK comparisons? Yeah. John, do you wanna just touch on that? Yeah, Eddie, you know, one of the things that the team beyond sort of the POD, right, is that they put the formulations together. Obviously, Trudhesa is a liquid formulation because we used Migranal, which had been on the market for 30 years. With INP105 program, that is a dry powder formulation that was specifically made for olanzapine. It's in a device that was specifically made for the dry powder, and it works very similarly to the liquid, which is one of the ideal pieces of the POD platform. We don't anticipate any additional sort of risks with the dry powder versus the liquid. That was one of the reasons why we did the phase I to just look at the safety. Obviously, Adrian's talked to the efficacy, which was better than intramuscular injection. We're pretty bullish on the prospects for this, especially given how olanzapine works on aggression in multiple other sort of indications. Thank you so much, and congrats again on the progress. Thank you very much. Your next question comes from the line of Laura Chico from Wedbush. Your line is open. Hey, good morning, guys. Thank you for taking the question. I just wanted to drill into the script metrics that you provided. So you're indicating a target of about 3,000-4,000 scripts here. Could you talk a little bit more about your assumptions to get to that level? I'm assuming no further access wins are necessary to get to that point. Then also on the 750 unique prescribers, would that be about or roughly a doubling on the number of prescriptions per doc, if I'm doing the math right. I guess I'm curious, how do you see that actually breaking out in terms of within the super target demographic versus broader neuro or PCP setting? Thanks, and I have one follow-up. Yep. Len, maybe I can ask you to comment, and then I'll add to that. Sure. Thanks. Thanks, Laura. If you look, you know, back at some of the slides, you could see the depth that starts to get driven, particularly by our super targets. The 750 number isn't just super targets, that's all targets. However, we do anticipate a good number of those will be super targets. You start to see, for example, you know, the average number of prescriptions for super targets right now is 4.2. You compare that to targets, it's a bit less. The same kind of metric follows with neurologists versus PCPs. Neurologists average about 2.1, whereas primary care physicians average about 1.5. You start to get to the 750 number through the expansion and the time it takes for our sales force to gain access to the various targets that we have. One of the great things that we're seeing, and you see that both in the metrics against UBRELVY and Nurtec, but also just in the sheer number of prescriptions each one of the super targets begins to prescribe as they get on board and begin to give it to their patients. You know, those are the two things that we're using to wind up at that 3,000-4,000 and just some momentum that we see building in the field. Okay, thanks. Then maybe just one I guess, obviously, it's early days here on the launch so far, but any anecdotal experience you can share in terms of the garden variety patient trying Trudhesa. I think, Adrian, to your point, you gave some commentary or color around this being in the post triptan market, but I'm also curious kind of what about the physicians prescribing it? And it sounds like the majority are kind of tilted towards the super users that are familiar with DHE, but any others kind of branching out? I guess I'd be curious in kind of anecdotal feedback so far on prescriber patterns. Yes, I think, very good question. I think, clearly two of the things we're tracking, obviously, is physician feedback that they are getting from patients. Clearly I think getting more and more information on how patients are finding the product. I think, you are correct. I think, clearly a lot of our efforts in roll-outs have been with our super targets and physicians who are well aware of the benefits of DHE. They've just been frustrated. They've never been able to deliver it in that consistent and predictable way. Although this week we had an example of neurologists whose daughter actually was a key migraine sufferer. He prescribed the product for his daughter. This is just an anecdote, but this is where we are at this point in time. Based on the feedback from his daughter, who was, of course, using his words deliriously happy, he immediately wrote 14 prescriptions. I think the product clearly works. We've seen a number of examples of that where patients are actually finding that the efficacy that they've wanted on demand is there for the taking. We've had a number of anecdotal stories like that. Again, we're gonna be collecting these over the course of time so that we can translate those into information to share on a more widely basis. So far so good. I think, this product works and clearly we just wanted to get into patients' hands, and it's then when they start to see the efficacy. Len, do you wanna add anything more to that? No, I think that's it. I think as Laura said, it is still early days, and one of the things we're excited about is that as patients get experience and come back to their neurologist or their headache specialist and share the success with Trudhesa, we think that's just going to build on itself, and provide that feedback loop, which is why we have that bridge program in place, so that patients get that, you know, get that satisfaction from trying the drug and give the feedback right to the physicians. Great. I'll try to sneak one last one in. I think there's some phase III data coming up for brexpiprazole in the autism space. I think that's arriving probably the first half of 2022. Any thoughts on potential read-through to your olanzapine efforts, if at all? Thanks, guys. Yeah. John, do you wanna comment on that? Yeah, Laura, I think it's a great question. I'm just gonna go back to the fact that we know olanzapine works with aggressions, right? Bipolar, schizophrenia, and others. I think it's got a well-known track record of safety. We're focusing on those pieces as we head into this aggression in autism. Again, given the past track record and the fact that atypical antipsychotics, you know, orally are given to this population, we think this PRN usage of 105 is gonna be very, very attractive in the marketplace. Thanks very much. We have no further questions at this time. I would now like to turn the call back to Adrian Adams for any closing remarks. Thank you very much, Operator. Thank you all for joining us this morning. We look forward to updating you on our continued progress as we complete 2021 and move into what we believe will be an equally exciting 2022 as we continue to create value for patients, healthcare professionals, and each and every one of you and the shareholders we serve. Thank you so much. This concludes today's conference call. Thank you for participating. You may now disconnect.